Effect of ezetimibe on PCSK9 concentrations in patients with type 2 diabetes and hypercholesterolemia

Effect of ezetimibe on PCSK9 concentrations in patients with type 2 diabetes and hypercholesterolemia - Effect of ezetimibe on PCSK9 concentrations in patients with type 2 diabetes and hypercholesterolemia

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000016112

Enrollment

Registered

2017-03-01

Start date

2017-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dyslipidemia

Interventions

ezetimibe treatment in patients with or without statin therapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with type 2 diabetes and hypercholesterolemia with or without statin therapy

Exclusion criteria

Exclusion criteria: 1) Triglyceride over 400mg/dl 2) Patients receiving insulin 3) Pregnant 4) Subjects who is allergic to ezetimibe 5) Severe liver disease 6) Serum creatinine over 2 mg/dl 7) Patients with acute myocardial infarction, unstable angina, or stroke within 3 months 8) Secondary hypercholesterolemia, familial hypercholesterolemia 9) Patients receiving ezetimibe or fibrates 10) Unsuitable patients for this study by physicians decision

Design outcomes

Primary

Measure	Time frame
Change in PCSK9 concentration	—

Countries

Japan

Contacts

Public ContactToru Miyoshi

Okayama University Graduate School of. Medicine, Dentistry and Pharmaceutical Sciences Cardiovascular Medicine

miyoshit@cc.okayama-u.ac.jp086-235-7351

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026